Bristol Myers Squibb (BMY) Interest Expenses (2012 - 2013)
Bristol Myers Squibb (BMY) reported Interest Expenses of $50.0 million for Q1 2013, up 19.05% year-over-year from $42.0 million in Q1 2012, and up 19.05% on a QoQ basis from $42.0 million in Q1 2012.
Bristol Myers Squibb (BMY) has 2 years of Interest Expenses data on file, last reported at $50.0 million in Q1 2013.
- Quarterly Interest Expenses rose 19.05% year-over-year to $50.0 million in Q1 2013, while the trailing twelve-month figure through Dec 2013 was $50.0 million (up 19.05% YoY) and the FY2012 annual result came in at $182.0 million, up 25.52% from the prior year.
- Interest Expenses improved to $50.0 million in Q1 2013 per BMY's latest filing, from $42.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $50.0 million in Q1 2013 and bottomed at $42.0 million in Q1 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | -343.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 272.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2012 | 42.00 Mn |
| Mar 31, 2012 | 42.00 Mn |